Allergan

Contact
allergan.com
+1714246-4500

Allergan, Inc.

2525 Dupont Drive
92623 Irvine
USA
+1714246-4500
allergan.com
Contact
Profile Products News
Contact

About Allergan

Allergan, Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, biologics and medical devices that enable people to live life to its greatest potential — to see more clearly, move more freely, express themselves more fully.

Read more about Allergan
Facts about Allergan
  • Focus : Manufacturer
  • Industry : Pharma

Product portfolio of Allergan

Product portfolio

Show all

News about Allergan

Allergan

20-Oct-2017 | politics & laws

Protecting patents by Native Americans

By using a novel patent strategy companies try to protect their intellectual property in the US. And this is how it works: Giving your patent to a body ...

Read news
Allergan

25-Nov-2015 | business & finance

Pfizer and Allergan to Combine

Pfizer Inc. and Allergan plc announced that their boards of directors have unanimously approved, and the companies have entered into, a definitive merger ...

Read news
Allergan

07-Sep-2015 | business & finance

Allergan to Acquire Glaucoma Treatment Company AqueSys

Allergan plc and AqueSys, Inc. announced that they have entered into an agreement under which Allergan will acquire AqueSys in an all-cash transaction. ...

Read news
Allergan

23-Jan-2013 | research and development

Molecular Partners: Results from Phase I/II Clinical Trial of its anti-VEGF DARPin MP0112 in Diabetic Macular Edema

Molecular Partners announced that the results of a Phase I/II study evaluating the safety and preliminary activity of MP0112, a long-acting anti-VEGF ...

Read news
Allergan

23-Aug-2012 | business & finance

Allergan and Molecular Partners Enter into Exclusive Alliance

Global partnership will develop novel products for eye diseases

Read news
Allergan

11-Apr-2012 | research and development

Molecular Partners comments on Allergan’s progress in Phase IIa Retinal Disease Trial using anti-VEGF DARPin

Molecular Partners AG commented on the recent progress with its anti-VEGF DARPin (AGN-150998/MP0112), which is being developed in partnership with Allergan ...

Read news
Allergan

08-Nov-2011 | business & finance

ExonHit Extends Strategic Collaboration with Allergan

Agreement to extend the collaboration until December 2013

Read news
Allergan

05-May-2011 | business & finance

Allergan and Molecular Partners enter into an exclusive license agreement for MP0112 for the treatment of retinal diseases

Allergan, Inc. and Molecular Partners AG announced that they have entered into a license agreement for MP0112, a phase II proprietary therapeutic DARPin® ...

Read news
Show more news about Allergan

Here you will find Allergan, Inc.